The Kenya Medical Association (KMA) has endorsed the rollout of lenacapavir, a new long-acting injectable HIV prevention option, while emphasizing the critical need for robust testing, safety monitoring, and sustainable financing.

• KMA has welcomed the introduction of lenacapavir as a breakthrough HIV prevention method.
• The association urges prioritization of comprehensive HIV testing, rigorous safety monitoring, and sustainable financial models for successful implementation.
• Lenacapavir, administered via two subcutaneous injections every 26 weeks after an oral loading dose, is licensed for HIV-negative individuals and should not be used by those already living with HIV.